{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:42:38Z","timestamp":1782963758283,"version":"3.54.5"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although vancomycin is commonly used to treat methicillin-resistant coagulase-negative staphylococci (MRCoNS) infections, there are no clear guidelines for the optimal 24 h AUC24\/MIC ratio. This study aimed to determine the target AUC24\/MIC ratio associated with vancomycin-treated MRCoNS infection outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicentre retrospective cohort study included adult patients who received vancomycin for \u22655\u2005days for bloodstream infections caused by MRCoNS between January 2018 and December 2023. Primary outcome was treatment success, defined as a composite of survival beyond 30\u2005days, clinical success and microbiological eradication. Secondary outcomes included 30-day mortality, clinical success, microbiological eradication and nephrotoxicity. Receiver operating characteristic (ROC) curve analysis was used to identify the AUC24\/MIC cut-off for treatment success. Multivariate regression analysis was used to determine the association between AUC24\/MIC and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study included 147 patients. ROC analysis identified a target AUC24\/MIC \u2265373 for treatment success. The overall treatment success rate (70.1%) was significantly higher in the above-average AUC24\/MIC cut-off group (83.1%) than that in the below AUC24\/MIC cut-off group (57.9%). Multivariate analysis confirmed that AUC24\/MIC \u2265373 was an independent predictor (adjusted OR\u200a=\u200a10.227; 95% CI\u200a=\u200a3.585\u201329.171). The 30-day mortality and microbiological eradication rates differed significantly between the below- and above-cut-off groups, whereas nephrotoxicity rates were comparable among the groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In treating MRCoNS infections, vancomycin AUC24\/MIC ratio \u2265373 was independently associated with favourable treatment outcomes. However, further prospective studies are required to confirm this target owing to the retrospective nature of this study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae442","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T16:05:11Z","timestamp":1734451511000},"page":"538-546","source":"Crossref","is-referenced-by-count":2,"title":["Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24\/MIC ratio: a multicentre retrospective cohort study"],"prefix":"10.1093","volume":"80","author":[{"given":"Yuki","family":"Hanai","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiju","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yamanashi Prefectural Central Hospital , Yamanashi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Hanawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kameda Medical Center , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-8592","authenticated-orcid":false,"given":"Hideki","family":"Hashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Bay Urayasu Ichikawa Medical Center , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of General Medicine and Emergency Care (Infectious Diseases), Toho University Omori Medical Center , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Toho University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-6564","authenticated-orcid":false,"given":"Sohei","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Toho University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yokoo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toho University Omori Medical Centre , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Uekusa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Asakawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yamanashi Prefectural Central Hospital , Yamanashi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kameda Medical Center , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kameda Medical Center , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Tsujimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kameda Medical Center , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Namiki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Bay Urayasu Ichikawa Medical Center , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Isoda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toho University Omori Medical Centre , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-0670","authenticated-orcid":false,"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3575-0448","authenticated-orcid":false,"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"2025020223515887200_dkae442-B1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1128\/CMR.7.1.117","article-title":"Update on clinical significance of coagulase-negative staphylococci","volume":"7","author":"Kloos","year":"1994","journal-title":"Clin Microbiol Rev"},{"key":"2025020223515887200_dkae442-B2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s10096-002-0799-9","article-title":"Characterisation of coagulase-negative staphylococci isolated from blood infections: incidence, susceptibility to glycopeptides, and molecular epidemiology","volume":"21","author":"Boisson","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025020223515887200_dkae442-B3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2025020223515887200_dkae442-B4","first-page":"111","article-title":"Identificaci\u00f3n de estafiloc\u00f3cos coagulasa negativos en pacientes hospitalizados [Identification of coagulase-negative staphylococci in hospitalized patients]","volume":"10","author":"Pinilla","year":"1985","journal-title":"Rev Med Panama"},{"key":"2025020223515887200_dkae442-B5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ijantimicag.2010.11.020","article-title":"Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin","volume":"37","author":"Stuart","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223515887200_dkae442-B6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1099\/jmm.0.000372","article-title":"Coagulase-negative staphylococci: pathogenesis, occurrence of antibiotic resistance genes and in vitro effects of antimicrobial agents on biofilm-growing bacteria","volume":"65","author":"Szczuka","year":"2016","journal-title":"J Med Microbiol"},{"key":"2025020223515887200_dkae442-B7","first-page":"1117","article-title":"Methicillin resistant coagulase negative staphylococcus: from colonizer to a pathogen","volume":"29","author":"Gilani","year":"2016","journal-title":"Pak J Pharm Sci"},{"key":"2025020223515887200_dkae442-B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025020223515887200_dkae442-B9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2025020223515887200_dkae442-B10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","article-title":"Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review","volume":"68","author":"Elyasi","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"2025020223515887200_dkae442-B11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/AAC.01088-08","article-title":"Vancomycin ototoxicity: a reevaluation in an era of increasing doses","volume":"53","author":"Forouzesh","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223515887200_dkae442-B12","doi-asserted-by":"publisher","first-page":"e0224561","DOI":"10.1371\/journal.pone.0224561","article-title":"Long-term vancomycin use had low risk of ototoxicity","volume":"14","author":"Humphrey","year":"2019","journal-title":"PLoS One"},{"key":"2025020223515887200_dkae442-B13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2025020223515887200_dkae442-B14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025020223515887200_dkae442-B15","doi-asserted-by":"publisher","first-page":"e01293-17","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223515887200_dkae442-B16","doi-asserted-by":"publisher","first-page":"e0146224","DOI":"10.1371\/journal.pone.0146224","article-title":"Association between the AUC0-24\/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis","volume":"11","author":"Men","year":"2016","journal-title":"PLoS One"},{"key":"2025020223515887200_dkae442-B17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223515887200_dkae442-B18","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223515887200_dkae442-B19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s11095-021-03030-y","article-title":"Performance of area under the concentration-time curve estimations of vancomycin with limited sampling by a newly developed web application","volume":"38","author":"Oda","year":"2021","journal-title":"Pharm Res"},{"key":"2025020223515887200_dkae442-B20","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1111\/cts.13626","article-title":"Model-informed precision dosing of vancomycin for rapid achievement of target area under the concentration-time curve: a simulation study","volume":"16","author":"Oda","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2025020223515887200_dkae442-B21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00007691-199804000-00003","article-title":"Population pharmacokinetics of vancomycin in Japanese adult patients","volume":"20","author":"Yasuhara","year":"1998","journal-title":"Ther Drug Monit"},{"key":"2025020223515887200_dkae442-B22","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1001\/archinternmed.2011.318","article-title":"Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms","volume":"171","author":"Schuetz","year":"2011","journal-title":"Arch Intern Med"},{"key":"2025020223515887200_dkae442-B23","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s10096-016-2691-z","article-title":"Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction","volume":"35","author":"Ueda","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025020223515887200_dkae442-B24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"Suppl 1","key":"2025020223515887200_dkae442-B25","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025020223515887200_dkae442-B26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025020223515887200_dkae442-B27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jiac.2013.12.009","article-title":"Influence of antimicrobial regimen on decreased in-hospital mortality of patients with MRSA bacteremia","volume":"20","author":"Kaku","year":"2014","journal-title":"J Infect Chemother"},{"key":"2025020223515887200_dkae442-B28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s15010-014-0689-y","article-title":"Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis","volume":"43","author":"Ziegler","year":"2015","journal-title":"Infection"},{"key":"2025020223515887200_dkae442-B29","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1128\/CMR.00109-13","article-title":"Coagulase-negative staphylococci","volume":"27","author":"Becker","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 2","key":"2025020223515887200_dkae442-B30","doi-asserted-by":"publisher","first-page":"ii65","DOI":"10.1093\/jac\/dkn353","article-title":"Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06","volume":"62","author":"Hope","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2025020223515887200_dkae442-B31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2169\/internalmedicine.56.7715","article-title":"Clinical characteristics of methicillin-resistant coagulase-negative staphylococcal bacteremia in a tertiary hospital","volume":"56","author":"Yamada","year":"2017","journal-title":"Intern Med"},{"key":"2025020223515887200_dkae442-B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijantimicag.2013.10.017","article-title":"Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Jung","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223515887200_dkae442-B33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5114\/ait.2019.87362","article-title":"Association between single trough-based area under the curve estimation of vancomycin and treatment outcome among methicillin-resistant Staphylococcus aureus bacteremia patients","volume":"51","author":"Makmor-Bakry","year":"2019","journal-title":"Anaesthesiol Intensive Ther"},{"key":"2025020223515887200_dkae442-B34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/23744235.2017.1323346","article-title":"Prognostic factors associated with 30-day in-hospital mortality in coagulase-negative Staphylococcus bacteraemia: no impact of vancomycin minimum inhibitory concentration","volume":"49","author":"Hentzien","year":"2017","journal-title":"Infect Dis"},{"key":"2025020223515887200_dkae442-B35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13756-019-0523-5","article-title":"The species distribution, antimicrobial resistance and risk factors for poor outcome of coagulase-negative staphylococci bacteraemia in China","volume":"8","author":"Cui","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025020223515887200_dkae442-B36","doi-asserted-by":"publisher","first-page":"ofz077","DOI":"10.1093\/ofid\/ofz077","article-title":"The impact of concomitant empiric cefepime on patient outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections treated with vancomycin","volume":"6","author":"Zasowski","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025020223515887200_dkae442-B37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40121-020-00292-8","article-title":"Monotherapy with vancomycin or daptomycin versus combination therapy with \u03b2-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective cohort analysis","volume":"9","author":"Alosaimy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2025020223515887200_dkae442-B38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/postgradmedj-2020-139512","article-title":"What do beta-lactams add to vancomycin or daptomycin in the treatment of patients with methicillin-resistant Staphylococcus aureus bacteraemia? A review","volume":"98","author":"Garc\u00eda Aragon\u00e9s","year":"2022","journal-title":"Postgrad Med J"},{"key":"2025020223515887200_dkae442-B39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/phar.1638","article-title":"Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational studies","volume":"35","author":"Prybylski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2025020223515887200_dkae442-B40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/0897190014546114","article-title":"Vancomycin nephrotoxicity: a review","volume":"27","author":"Mergenhagen","year":"2014","journal-title":"J Pharm Pract"},{"key":"2025020223515887200_dkae442-B41","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/1060028017720946","article-title":"Intravenous vancomycin associated with the development of nephrotoxicity in patients with class III obesity","volume":"51","author":"Choi","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2025020223515887200_dkae442-B42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jiac.2020.10.014","article-title":"Comparison of trough concentration and area under the curve of vancomycin associated with the incidence of nephrotoxicity and predictors of a high trough level","volume":"27","author":"Suzuki","year":"2021","journal-title":"J Infect Chemother"},{"key":"2025020223515887200_dkae442-B43","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025020223515887200_dkae442-B44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/538\/61217003\/dkae442.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/538\/61217003\/dkae442.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T23:52:09Z","timestamp":1738540329000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/2\/538\/7926781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,17]]},"published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae442","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,17]]}}}